ESMO 2019 | CRT and Debio1143 for treatment of LA SCCHN
Jean Bourhis
Jean Bourhis, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland outlines the initial findings in this double-blind randomized phase II trial regarding the use of cisplatin chemoradiation (CRT) plus debio 1143 in the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Related videos

REACH safety data: avelumab plus RT-cetuximab in LA SCCHN
Jean Bourhis

NPC communication between the West and China
Ming-Yuan Chen

Phase III trial: chemotherapy plus local-regional radiotherapy in pmNPCC
Ming-Yuan Chen

Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe

The value of PD-L1 as a biomarker beyond lung cancers
Kevin Harrington
More from Jean Bourhis